- Home
- HPS vs SIGA Comparison
HPS vs SIGA Comparison
Compare HPS & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPS
- SIGA
- Stock Information
- Founded
- HPS 2003
- SIGA 1995
- Country
- HPS United States
- SIGA United States
- Employees
- HPS N/A
- SIGA N/A
- Industry
- HPS Investment Managers
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- HPS Finance
- SIGA Health Care
- Exchange
- HPS Nasdaq
- SIGA Nasdaq
- Market Cap
- HPS 475.4M
- SIGA 515.1M
- IPO Year
- HPS N/A
- SIGA 1997
- Fundamental
- Price
- HPS $15.58
- SIGA $8.95
- Analyst Decision
- HPS
- SIGA
- Analyst Count
- HPS 0
- SIGA 0
- Target Price
- HPS N/A
- SIGA N/A
- AVG Volume (30 Days)
- HPS 58.4K
- SIGA 504.0K
- Earning Date
- HPS 01-01-0001
- SIGA 11-06-2025
- Dividend Yield
- HPS 8.62%
- SIGA 6.70%
- EPS Growth
- HPS N/A
- SIGA N/A
- EPS
- HPS N/A
- SIGA 1.14
- Revenue
- HPS N/A
- SIGA $179,639,422.00
- Revenue This Year
- HPS N/A
- SIGA N/A
- Revenue Next Year
- HPS N/A
- SIGA $115.06
- P/E Ratio
- HPS N/A
- SIGA $7.86
- Revenue Growth
- HPS N/A
- SIGA 3.86
- 52 Week Low
- HPS $11.79
- SIGA $4.95
- 52 Week High
- HPS $15.40
- SIGA $9.62
- Technical
- Relative Strength Index (RSI)
- HPS 73.09
- SIGA 52.77
- Support Level
- HPS $15.24
- SIGA $8.72
- Resistance Level
- HPS $15.43
- SIGA $9.29
- Average True Range (ATR)
- HPS 0.16
- SIGA 0.32
- MACD
- HPS 0.01
- SIGA -0.03
- Stochastic Oscillator
- HPS 85.38
- SIGA 43.82
About HPS John Hancock Preferred Income Fund III Preferred Income Fund III
John Hancock Preferred Income Fund III is a closed-end, diversified management investment company. Its investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve the objectives by investing a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. The portfolio composition of the company consists of the U.S. preferred securities, foreign preferred securities, common stocks, corporate bonds, and the short-term investments.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.